Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503)

Publication date: Available online 12 November 2018Source: The Lancet Respiratory MedicineAuthor(s): Nasser K Altorki, Xiaofei Wang, Dennis Wigle, Lin Gu, Gail Darling, Ahmad S Ashrafi, Rodney Landrenau, Daniel Miller, Moishe Liberman, David R Jones, Robert Keenan, Massimo Conti, Gavin Wright, Linda J Veit, Suresh S Ramalingam, Mohamed Kamel, Harvey I Pass, John D Mitchell, Thomas Stinchcombe, Everett VokesSummaryBackgroundIncreased detection of small-sized, peripheral, non-small-cell lung cancer has renewed interest in sublobar resection instead of lobectomy, the traditional standard of care for early-stage lung cancer. We aimed to assess morbidity and mortality associated with lobar and sublobar resection for early-stage lung cancer.MethodsCALGB/Alliance 140503 is a multicentre, international, non-inferiority, phase 3 trial in patients with peripheral non-small-cell lung cancer clinically staged as T1aN0. Patients were recruited from 69 academic and community-based institutions in Australia, Canada, and the USA. Patients were randomly assigned intraoperatively to either lobar or sublobar resection. The random assignment was based on permuted block randomisation without concealment and was stratified according to radiographic tumour size, histology, and smoking status. The primary endpoint of the trial is disease-free survival; here, we report a post-hoc, exploratory, comparative analysis of perioperative mortality and morbidity associated with lobar and sublobar resection. ...
Source: The Lancet Respiratory Medicine - Category: Respiratory Medicine Source Type: research